National survey of Australian cardiologists' beliefs and practice regarding screening, diagnosis and management of depression in cardiac patients

  • Mr Andrew Stewart, Austin Health, Australia
  • A Driscol, Monash University, Australia
  • David Hare, University of Melbourne, Australia

Over one third of cardiac patients are depressed. It is unclear whether depression is thought important by cardiologists. Purpose: (1) Examine cardiologists' beliefs and practice in relation to depression screening, diagnosis, treatment and referral Method: A national survey of all Australian cardiology members of the Cardiac Society of Australia & New Zealand (CSANZ) was conducted with a single page questionnaire. Results: Sixty percent of members responded (511 of 822 eligible). The majority screened for depression "sometimes", 49.8%, and 32.4%, "often" or "always". While 96.8% reported using no standard screening tool, 71.3% reported they would use a short screening questionnaire if available. For responsibility of depression identification, General Practitioners (GPs) were highest ranked, followed by cardiologists and cardiac rehabilitation. For treatment of depression, GPs were ranked highest, followed closely by psychiatrists, then cardiologists and psychologists. Most referred patients "sometimes" (40%) to GPs, psychiatrists and psychologists, and 56% of all surveyed "very much" wanted feedback on patient progress. Most reported never treating depression with antidepressant medication (40%), and the strongest predictor treatment was confidence in treating depression (r=0.616, p<0.0001), followed by, nomination of cardiologists for treatment (0.387, p<0.0001), belief in antidepressant efficacy (r=0.358, p<0.0001), and depression having an etiological role in CVD (r=0.158, p<0.0001). Most believed depression was only "slightly" related to CVD development (41.2%), but "moderately" related to cardiac events and death, 53% and 49% respectively. Conclusions: Australian cardiologists are interested in depression but don't use diagnostic screening tools. These results will assist the development of clinical pathways.